Treatment effects in a transgenic mouse model of alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization

M. Marjańska; S. D. Weigand; G. Preboske; T. M. Wengenack; R. Chamberlain; G. L. Curran; J. F. Poduslo; M. Garwood; D. Kobayashi; J. C. Lin; C. R. Jack

doi:10.1016/j.neuroscience.2013.11.052

Treatment effects in a transgenic mouse model of alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization

M. Marjańska, S. D. Weigand, G. Preboske, T. M. Wengenack, R. Chamberlain, G. L. Curran, J. F. Poduslo, M. Garwood, D. Kobayashi, J. C. Lin, C. R. Jack

Radiology

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Despite the enormous public health impact of Alzheimer's disease (AD), no disease-modifying treatment has yet been proven to be efficacious in humans. A rate-limiting step in the discovery of potential therapies for humans is the absence of efficient non-invasive methods of evaluating drugs in animal models of disease. Magnetic resonance spectroscopy (MRS) provides a non-invasive way to evaluate the animals at baseline, at the end of treatment, and serially to better understand treatment effects. In this study, MRS was assessed as potential outcome measure for detecting disease modification in a transgenic mouse model of AD. Passive immunization with two different antibodies, which have been previously shown to reduce plaque accumulation in transgenic AD mice, was used as intervention. Treatment effects were detected by MRS, and the most striking finding was attenuation of myo-inositol (mIns) increases in APP-PS1 mice with both treatments. Additionally, a dose-dependent effect was observed with one of the treatments for mIns. MRS appears to be a valid in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies. Because it is noninvasive, and can detect treatment effects, use of MRS-based endpoints could substantially accelerate drug discovery.

Original language	English (US)
Pages (from-to)	94-100
Number of pages	7
Journal	Neuroscience
Volume	259
DOIs	https://doi.org/10.1016/j.neuroscience.2013.11.052
State	Published - Feb 14 2014

Bibliographical note

Funding Information:
The authors, except for Dione Kobayashi and John C. Lin, declare no competing financial interest. Dione Kobayashi and John C. Lin are employees of Rinat, Pfizer Inc. This work was supported by Pfizer-Rinat , NIH grants: BTRC P41 RR008079 , P41 EB015894 , P30 NS057091 , RO1 AG011378 , and the W.M. Keck Foundation. The authors would like to thank James Kupiec and Jaume Pons for helpful discussions and for initiating research support; Dawn M. Gregor for mouse breeding and genotypic; Angela L. Styczynski Snyder, Nathaniel J. Powell and Angela Polk for data acquisition; Christine O’Brien for animal care; Karin Wallace and Kelly Bales for brain homogenate assay support; Danielle Pappas for plasma drug level assays.

Keywords

MRS
Myo-inositol
N-acetylaspartate
Treatment detection

Access

10.1016/j.neuroscience.2013.11.052

OpenUrl availability

Full text

Cite this

Marjańska, M., Weigand, S. D., Preboske, G., Wengenack, T. M., Chamberlain, R., Curran, G. L., Poduslo, J. F., Garwood, M., Kobayashi, D., Lin, J. C., & Jack, C. R. (2014). Treatment effects in a transgenic mouse model of alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization. Neuroscience, 259, 94-100. https://doi.org/10.1016/j.neuroscience.2013.11.052

Marjańska, M, Weigand, SD, Preboske, G, Wengenack, TM, Chamberlain, R, Curran, GL, Poduslo, JF, Garwood, M, Kobayashi, D, Lin, JC & Jack, CR 2014, 'Treatment effects in a transgenic mouse model of alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization', Neuroscience, vol. 259, pp. 94-100. https://doi.org/10.1016/j.neuroscience.2013.11.052

@article{26026f9c2c944b1abbf258f079b06439,

title = "Treatment effects in a transgenic mouse model of alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization",

abstract = "Despite the enormous public health impact of Alzheimer's disease (AD), no disease-modifying treatment has yet been proven to be efficacious in humans. A rate-limiting step in the discovery of potential therapies for humans is the absence of efficient non-invasive methods of evaluating drugs in animal models of disease. Magnetic resonance spectroscopy (MRS) provides a non-invasive way to evaluate the animals at baseline, at the end of treatment, and serially to better understand treatment effects. In this study, MRS was assessed as potential outcome measure for detecting disease modification in a transgenic mouse model of AD. Passive immunization with two different antibodies, which have been previously shown to reduce plaque accumulation in transgenic AD mice, was used as intervention. Treatment effects were detected by MRS, and the most striking finding was attenuation of myo-inositol (mIns) increases in APP-PS1 mice with both treatments. Additionally, a dose-dependent effect was observed with one of the treatments for mIns. MRS appears to be a valid in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies. Because it is noninvasive, and can detect treatment effects, use of MRS-based endpoints could substantially accelerate drug discovery.",

keywords = "MRS, Myo-inositol, N-acetylaspartate, Treatment detection",

author = "M. Marja{\'n}ska and Weigand, {S. D.} and G. Preboske and Wengenack, {T. M.} and R. Chamberlain and Curran, {G. L.} and Poduslo, {J. F.} and M. Garwood and D. Kobayashi and Lin, {J. C.} and Jack, {C. R.}",

note = "Funding Information: The authors, except for Dione Kobayashi and John C. Lin, declare no competing financial interest. Dione Kobayashi and John C. Lin are employees of Rinat, Pfizer Inc. This work was supported by Pfizer-Rinat , NIH grants: BTRC P41 RR008079 , P41 EB015894 , P30 NS057091 , RO1 AG011378 , and the W.M. Keck Foundation. The authors would like to thank James Kupiec and Jaume Pons for helpful discussions and for initiating research support; Dawn M. Gregor for mouse breeding and genotypic; Angela L. Styczynski Snyder, Nathaniel J. Powell and Angela Polk for data acquisition; Christine O{\textquoteright}Brien for animal care; Karin Wallace and Kelly Bales for brain homogenate assay support; Danielle Pappas for plasma drug level assays.",

year = "2014",

month = feb,

day = "14",

doi = "10.1016/j.neuroscience.2013.11.052",

language = "English (US)",

volume = "259",

pages = "94--100",

journal = "Neuroscience",

issn = "0306-4522",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Treatment effects in a transgenic mouse model of alzheimer's disease

T2 - A magnetic resonance spectroscopy study after passive immunization

AU - Marjańska, M.

AU - Weigand, S. D.

AU - Preboske, G.

AU - Wengenack, T. M.

AU - Chamberlain, R.

AU - Curran, G. L.

AU - Poduslo, J. F.

AU - Garwood, M.

AU - Kobayashi, D.

AU - Lin, J. C.

AU - Jack, C. R.

N1 - Funding Information: The authors, except for Dione Kobayashi and John C. Lin, declare no competing financial interest. Dione Kobayashi and John C. Lin are employees of Rinat, Pfizer Inc. This work was supported by Pfizer-Rinat , NIH grants: BTRC P41 RR008079 , P41 EB015894 , P30 NS057091 , RO1 AG011378 , and the W.M. Keck Foundation. The authors would like to thank James Kupiec and Jaume Pons for helpful discussions and for initiating research support; Dawn M. Gregor for mouse breeding and genotypic; Angela L. Styczynski Snyder, Nathaniel J. Powell and Angela Polk for data acquisition; Christine O’Brien for animal care; Karin Wallace and Kelly Bales for brain homogenate assay support; Danielle Pappas for plasma drug level assays.

PY - 2014/2/14

Y1 - 2014/2/14

N2 - Despite the enormous public health impact of Alzheimer's disease (AD), no disease-modifying treatment has yet been proven to be efficacious in humans. A rate-limiting step in the discovery of potential therapies for humans is the absence of efficient non-invasive methods of evaluating drugs in animal models of disease. Magnetic resonance spectroscopy (MRS) provides a non-invasive way to evaluate the animals at baseline, at the end of treatment, and serially to better understand treatment effects. In this study, MRS was assessed as potential outcome measure for detecting disease modification in a transgenic mouse model of AD. Passive immunization with two different antibodies, which have been previously shown to reduce plaque accumulation in transgenic AD mice, was used as intervention. Treatment effects were detected by MRS, and the most striking finding was attenuation of myo-inositol (mIns) increases in APP-PS1 mice with both treatments. Additionally, a dose-dependent effect was observed with one of the treatments for mIns. MRS appears to be a valid in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies. Because it is noninvasive, and can detect treatment effects, use of MRS-based endpoints could substantially accelerate drug discovery.

AB - Despite the enormous public health impact of Alzheimer's disease (AD), no disease-modifying treatment has yet been proven to be efficacious in humans. A rate-limiting step in the discovery of potential therapies for humans is the absence of efficient non-invasive methods of evaluating drugs in animal models of disease. Magnetic resonance spectroscopy (MRS) provides a non-invasive way to evaluate the animals at baseline, at the end of treatment, and serially to better understand treatment effects. In this study, MRS was assessed as potential outcome measure for detecting disease modification in a transgenic mouse model of AD. Passive immunization with two different antibodies, which have been previously shown to reduce plaque accumulation in transgenic AD mice, was used as intervention. Treatment effects were detected by MRS, and the most striking finding was attenuation of myo-inositol (mIns) increases in APP-PS1 mice with both treatments. Additionally, a dose-dependent effect was observed with one of the treatments for mIns. MRS appears to be a valid in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies. Because it is noninvasive, and can detect treatment effects, use of MRS-based endpoints could substantially accelerate drug discovery.

KW - MRS

KW - Myo-inositol

KW - N-acetylaspartate

KW - Treatment detection

UR - http://www.scopus.com/inward/record.url?scp=84891354025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891354025&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2013.11.052

DO - 10.1016/j.neuroscience.2013.11.052

M3 - Article

C2 - 24316473

AN - SCOPUS:84891354025

SN - 0306-4522

VL - 259

SP - 94

EP - 100

JO - Neuroscience

JF - Neuroscience

ER -

Treatment effects in a transgenic mouse model of alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this